1319 related articles for article (PubMed ID: 32531712)
21. Evaluation of the prognostic role of platelet-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
Xu H; He A; Liu A; Tong W; Cao D
Int Immunopharmacol; 2019 Dec; 77():105957. PubMed ID: 31677498
[TBL] [Abstract][Full Text] [Related]
22. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
[TBL] [Abstract][Full Text] [Related]
23. Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.
Zhao QT; Yuan Z; Zhang H; Zhang XP; Wang HE; Wang ZK; Duan GC
Int J Cancer; 2016 Jul; 139(1):164-70. PubMed ID: 26915723
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio as Prognostic Predictors for Hepatocellular Carcinoma Patients with Various Treatments: a Meta-Analysis and Systematic Review.
Zheng J; Cai J; Li H; Zeng K; He L; Fu H; Zhang J; Chen L; Yao J; Zhang Y; Yang Y
Cell Physiol Biochem; 2017; 44(3):967-981. PubMed ID: 29179180
[TBL] [Abstract][Full Text] [Related]
25. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors.
Pu D; Xu Q; Zhou LY; Zhou YW; Liu JY; Ma XL
Thorac Cancer; 2021 Nov; 12(21):2914-2923. PubMed ID: 34581010
[TBL] [Abstract][Full Text] [Related]
26. Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy.
Kartolo A; Holstead R; Khalid S; Emack J; Hopman W; Robinson A; Baetz T
Immunotherapy; 2020 Aug; 12(11):785-798. PubMed ID: 32657234
[No Abstract] [Full Text] [Related]
27. Prognostic Significance of Pretreatment Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, or Monocyte-to-Lymphocyte Ratio in Endometrial Neoplasms: A Systematic Review and Meta-analysis.
Leng J; Wu F; Zhang L
Front Oncol; 2022; 12():734948. PubMed ID: 35651788
[TBL] [Abstract][Full Text] [Related]
28. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis.
Gu XB; Tian T; Tian XJ; Zhang XJ
Sci Rep; 2015 Jul; 5():12493. PubMed ID: 26205001
[TBL] [Abstract][Full Text] [Related]
30. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract][Full Text] [Related]
31. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.
Shao Y; Wu B; Jia W; Zhang Z; Chen Q; Wang D
BMC Urol; 2020 Jul; 20(1):90. PubMed ID: 32631294
[TBL] [Abstract][Full Text] [Related]
33. Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker for Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen X; Meng F; Jiang R
Front Oncol; 2021; 11():746976. PubMed ID: 34900692
[TBL] [Abstract][Full Text] [Related]
34. Prognostic roles of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in ovarian cancer: a meta-analysis of retrospective studies.
Zhao Z; Zhao X; Lu J; Xue J; Liu P; Mao H
Arch Gynecol Obstet; 2018 Apr; 297(4):849-857. PubMed ID: 29368160
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Shoji F; Takeoka H; Kozuma Y; Toyokawa G; Yamazaki K; Ichiki M; Takeo S
Lung Cancer; 2019 Oct; 136():45-51. PubMed ID: 31437663
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib.
Chen T; Song C; Liang G; Xu X; Wang C; Zhang Z; Tang M
Dis Markers; 2022; 2022():5879137. PubMed ID: 35356064
[TBL] [Abstract][Full Text] [Related]
37. [Meta-analysis of Platelet Lymphocyte Ratio as A Prognostic Factor for
Non-small Cell Lung Cancer].
Chen H; Xue H; Liu W; Wu F; Wang Y; Gao H
Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):289-298. PubMed ID: 31109438
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.
Gu X; Sun S; Gao XS; Xiong W; Qin S; Qi X; Ma M; Li X; Zhou D; Wang W; Yu H
Sci Rep; 2016 Mar; 6():23893. PubMed ID: 27025911
[TBL] [Abstract][Full Text] [Related]
39. Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China.
Wang Y; Lu J; Wu C; Fei F; Chu Z; Lu P
Front Immunol; 2023; 14():1276107. PubMed ID: 38124739
[TBL] [Abstract][Full Text] [Related]
40. Prognostic role of the platelet to lymphocyte ratio (PLR) in the clinical outcomes of patients with advanced lung cancer receiving immunotherapy: A systematic review and meta-analysis.
Zhou K; Cao J; Lin H; Liang L; Shen Z; Wang L; Peng Z; Mei J
Front Oncol; 2022; 12():962173. PubMed ID: 36059629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
